 |
Also known as: Thalomid
The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.
Learn more about Thalidomide.
No reviews have yet been submitted. Be the first to review this drug.
CAMBRIDGE, Mass., January 23, 2012–Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced...
ZOLINZA in Combination with Bortezomib Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed and/or Refractory Multiple...
Dec 15, 2011 - Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against...
Dec 13, 2011 - Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported Phase I and...
ˆ’ VELCADE added to a standard frontline therapy demonstrates 43.9 percent overall survival improvement in landmark phase III VISTA trial ˆ’ ˆ’...
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and others.
To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2012 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
